1219728-20-7

SR7826 (10 mg/kg; oral gavage; once daily; for 11 days; hAPPJ20 mice) treatment significantly reduces the phosphorylation of cofilin at Ser3. SR7826 also increases both apical and basal thin spine density significantly in hAPPJ20 mice over mock-treated animals^[2].
The plasma pharmacokinetics studies on rats are investigated. After intravenous injection, the PK properties of SR7826 (compound 18b; 1mg/kg) with a Cl of 5.2 mL/min/kg, a T_1/2 of 2.2h, an AUC of 8.4 μM*h and a C_max of 7.7 μM, and has 36% oral bioavailability in rats (oral administration; 2mg/kg)^[1].